Association of XXXX Use with Outcomes in Advanced @entity1204 Treated with Chemotherapy.

@entity1 @entity1204 @entity6 @entity5 @entity2449
UNASSIGNED: There is increasing evidence that @entity2449 , a commonly used treatment for @entity6 , might have the potential to be repurposed as an economical and safe @entity5 therapeutic. The aim of this study was to determine whether stage III-IV or recurrent @entity1204 @entity1 who are using @entity2449 during treatment with chemotherapy have improved survival. To test this we analyzed a retrospective cohort of subjects at two independent institutions who received chemotherapy for stage III-IV or recurrent @entity1204 from 1992 to 2011. Diagnosis of @entity6 , @entity2449 use, demographics, @entity1204 clinico-pathologic parameters, and survival duration were abstracted. The primary outcome was overall survival. The final cohort included 349 @entity1 , 31 (8.9%) had @entity6 and used @entity2449 , 28 (8.0%) had @entity6 but did not use @entity2449 , and 291 (83.4%) did not have @entity6 . The results demonstrate that the median overall survival was 45.6 months for @entity1 with @entity6 who used @entity2449 compared to 12.5 months for @entity1 with @entity6 who did not use @entity2449 and 28.5 months for @entity1 without @entity6 (log-rank test comparing the three groups P = 0.006). In a model adjusted for confounders, the difference in survival between the three groups remained statistically significant (P = 0.023). The improvement in survival among @entity2449 users was not explained by better baseline health status or more aggressive use of chemotherapy. Overall, the findings in this retrospective cohort of @entity1204 @entity1 with stage III-IV or recurrent disease treated with chemotherapy indicate that @entity1 with @entity6 who were concurrently treated with @entity2449 survived longer than @entity1 with @entity6 who did not use @entity2449 .
